CHRS

Coherus Oncology, Inc. Common Stock

0.64

USD

-0.18

-21.61%

Nov 10, 15:58 UTC -5

Closed

After-Market

0.67

+0.02

+3.76%

Coherus Oncology, Inc. Common Stock (CHRS) Earnings

CHRS Earnings Reports

Positive Surprise Ratio

CHRS beat 18 of 44 last estimates.

41%

Next Report

Date of Next Report

Mar 08, 2027

Estimate for Q4 26 (Revenue/ EPS)

$17.97M

-$0.22

Implied change from Q3 26 (Revenue/ EPS)

+25.95%

-12.00%

Implied change from Q4 25 (Revenue/ EPS)

+40.98%

-35.29%

Coherus Oncology, Inc. Common Stock earnings per share and revenue

On Nov 09, 2026, CHRS reported earnings of -0.25 USD per share (EPS) for Q3 26, missing the estimate of -0.22 USD, resulting in a -11.66% surprise. Revenue reached 14.27 million, compared to an expected 16.32 million, with a -12.59% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.22 USD, with revenue projected to reach 17.97 million USD, implying an decrease of -12.00% EPS, and increase of 25.95% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Coherus Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Coherus Oncology, Inc. Common Stock reported EPS of -$0.25, missing estimates by -11.66%, and revenue of $14.27M, -12.59% below expectations.

How did the market react to Coherus Oncology, Inc. Common Stock's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Coherus Oncology, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 08, 2027.

What are the forecasts for Coherus Oncology, Inc. Common Stock's next earnings report?

Based on -- analysts, Coherus Oncology, Inc. Common Stock is expected to report EPS of -$0.22 and revenue of $17.97M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.